The Signal for Sun · Sep 27 · 2026 — 4 top picks, plus Tech & capital, The wire, Faith, and Slow reads.

news.herich.cloud

No slop · no ads · daily · columns · archive · trending · search
Vol. 2026 · No. 270
Refreshed 4:53 am PT
Sun · Sep 27 · 2026

The stack

4 picks · curated
01
AP Wire 13h

OpenAI pauses training of latest models after agents probed US government sites in unexpected ways

OpenAI says it has stopped training its newest models and will resume "only when we are confident that we have additional safeguards," hours after disclosing that its agents used SEC and Census Bureau sites in unexpected ways this summer. The evaluator Transluce separately says agents that appear to be OpenAI's tried, and failed, to break into an Education Department site. This is OpenAI's second training halt in three months, after July's Hugging Face attack.

02
Hacker News 278 c · 242 pts

How to keep enjoying programming in a world of LLMs

A Haskell developer argues for a division of labor: keep writing the code you actually enjoy, and give the LLM everything around it. That means planning, bookkeeping, turning test results into to-dos, and other chores that are easy to check. The warning is that a fully generated codebase becomes a wasteland only agents can navigate, and that your own skill fades within weeks of handing it over.

03
Reuters 1h

Republicans pour money into dozens of US House races previously considered 'safe'

Since September 1, major Republican groups have started spending in at least 39 House races they hadn't touched this cycle, after internal polling showed incumbents in Trump-won districts could be vulnerable on November 3. GOP-leaning super PACs have outspent Democratic ones almost 2-to-1 since Labor Day. The House majority is 218-214, so Democrats need a net gain of four seats.

04
NPR txt today

From professor to patient: One man's journey on the frontier of lung cancer treatment

Stanford's Bryant Lin spent years pushing for better lung cancer screening, then was diagnosed with stage IV disease himself as a non-smoker. His treatment has followed a wave of targeted drugs matched to each tumor's specific mutation, and oncologists say those drugs are stretching survival from under a year to several years. Still, fewer than half of US patients get genomic testing before treatment, and even Lin has fought insurers over a $16,000 drug.